Genmab — Januar 2020

[Doublo]

0,81 27-jan 0,02

Genmab 0,00 27-jan -0,58

[Doublo]

altså ingen over 0,5

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[Helge_LarsenPI-redaktør]

·

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma: https://onlinelibrary.wiley.com/doi/10.1002/cam4.2827

⁩ ⁦
⁩ ⁦

[transalp]

Go morgen..

[E_L]

Novartis "Ofatumumab (OMB157) was submitted to FDA and EMA (Jan) for treatment of RMS. - https://www.globenewswire.com/news-release/2020/01/29/1976523/0/en/Novartis-delivered-strong-sales-growth-margin-expansion-and-breakthrough-innovation-launching-five-NMEs-in-2019.html

[Bulder]

Helge, var det ikke nogenlunde samme mekanisme, Limo Chen fandt i lungecancer, og som vi havde store forhåbninger til?

[E_L]

it builds further on that article if i understand correctly

[Sukkeralf]

Uafhængige forskere tester Genmabs daratumumab mod Alzheimers

Biotekselskabet Genmabs helt store sællert testes nu som en mulig behandling af Alzheimers.

(medwatch.dk)

[Bulder]

Er det dette her: https://clinicaltrials.gov/ct2/show/NCT04070378

[JKY_VH]

tak Bulder, ser spændende ud.

[Solsen]

Vi og patienterne er utroligt heldige, hvis dara virker. Indikationen har et utal af biotech og pharma brændt naller på.

[bibob]

Ja, og hvis det ikke virker må man håbe det får en stille død. Vi har jo set hvordan kursen bliver banket ned, selv om et produkt ikke engang er indregnet. ;-).

[E_L]

Novartis still puts Ofa Regulatory
decisions and
opinions in H1 2020

[JKY_VH]

enig bibob

[Bulder]

Nice, thx E L

[E_L]

this is the NVS presentation pdf
if interested https://www.novartis.com/sites/www.novartis.com/files/q4-2019-investor-presentation.pdf

[E_L]

text from main slide: Ofatumumab (OMB157) is poised to set a new standard
for simple, broad and early B-cell therapy adoption

• Unsurpassed efficacy and favorable safety supporting broad and early use in RMS

[E_L]

45.9% risk reduction (p<0.001) in 24-week CDW post-hoc
analyses with revised definition used in OPERA trials1